Tim Petersen

Convergent Dental, Inc. is a privately owned dental equipment and technology company. The Company’s flagship product, Solea®, is the only CO2 laser to be cleared by the FDA for all-tissue indications and delivers virtually anesthesia-free, blood-free, pain-free experiences that dentists can rely on. Convergent Dental unites this novel technology with our unique Success Support community, enabling dentists to elevate and grow their practices through improved efficiency, patient experience, clinical effectiveness, and procedural expansion. CONTACT US Convergent Dental 100 Fifth Ave, Suite 1010 Waltham, MA 02451 P: 800.880.8589 E: info@convergentdental.com For the most up-to-date Career Postings, please visit our website.

NavvTrack® is an indoor navigation and location services technology for hospitals and health systems that uses Indoor Positioning technology (IPS) to provide Care Traffic Control. The platform, called NavvTrack®, was conceived at 877-bed Henry Ford Hospital and is being used to optimize patient transport, housekeeping, and central pharmacy deliveries. Henry Ford Hospital is 17-floors covering a total of 3,000,000 square feet and a part of the 6-hospital Henry Ford Health System. At Henry Ford Health System, NSI is partnering with Apple to leverage the “indoor GPS” to optimize mobile workflows and enable real-time healthcare. The platform requires no new infrastructure and can be enabled in a short time.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

SI-BONE® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (SI) joint. SI-BONE developed an innovative, patented implant to fuse the SI joint. The iFuse Implant System® provides a less invasive alternative to traditional sacroiliac (SI) joint fusion surgery and has been used in over 65,000 procedures to date. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com/risks. We are aware of active recruitment scams using the SI-BONE name, in which individuals pose as our recruiters and post fake remote job openings and make fake job offers on the Internet. Please note, we will never make an offer of employment without conducting multiple rounds of interviews face-to-face using secure video-conferencing technology. We will never ask candidates to cash checks or make a payment in order to be considered for a position. SI-BONE only uses company email addresses, which contain “@si-bone.com” to communicate with candidates. If you believe you’ve been a victim of a phishing scam, please visit the Cybersecurity & Infrastructure Security Agency at https://www.cisa.gov/be-cyber-smart/report-incident learn how to report it.

At iQue® (formerly Intellicyt), our mission is to enable bioscience enterprises to rapidly and cost effectively screen and profile disease- and physiologically-relevant model systems for phenotypic endpoints using cell-based and/or bead-based assays. We do this by providing easy-to-use hardware, software, and reagent systems that are optimized to conserve precious samples, use less reagent, and to minimize time-to-answer to both enhance workflow productivity and to preserve the biology of interest. All major pharmaceutical companies and many biotechnology companies and academic institutions have invested in iQue® Advanced Flow Cytometry Platform solutions, to give their cell-based screening campaigns the edge.

ConcertoCare is a tech-enabled, value-based provider of at-home, comprehensive care for seniors and other adults with unmet health and social needs. ConcertoCare deploys physician-led interdisciplinary teams— supported by its proprietary population health platform, Patient3D®, and clinical decision support tools — to manage the country's most medically and socially complex and costly patients in ways that keep them in their homes and out of the hospital. The results are better health outcomes, reduced costs, and a more personalized and integrated experience for patients and their families. ConcertoCare works with a wide variety of payers, and can partner with a patient’s current primary care physician or serve as the provider of record. Led by a world-class team of home-based care physicians, population health technology experts, former policymakers, and senior health plan executives, ConcertoCare serves seniors across the country. For more information, visit our website or follow us on Twitter.

At ArborMetrix, advancing healthcare through data science is our mission, and delivering high impact, intuitive technology and analytics is our passion. Our leading healthcare analytics solutions are proven to deliver targeted, clinically-deep insights that improve clinical outcomes, optimize financial performance, increase stakeholder value, and measure the real-world effectiveness of treatments and procedures, as well as medical device technologies and pharmaceuticals. Learn more how ArborMetrix can help you by visiting our website and exploring our solutions and capabilities. Become a part of ArborMetrix’s talented and growing team by exploring our current job openings.

MyHealthDirect, a leading provider of digital care coordination solutions, partners with many of the nation’s largest health systems and health plans to make it easy for people to access healthcare. Our intuitive technology guides consumers to the right care and enables real-time scheduling through any access channel: on the web, in call centers, and in provider offices. Through our consultative services, we bring insights and actionable analytics to our customers, improving outcomes and enhancing the patient experience.

Now a wholly owned subsidiary of BD, Accuri Cytometers, Inc. was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. With a tight focus on creating an affordable, robust, easy-to-use flow cytometer, our engineering team went back to basic principles and designed an innovative instrument from the ground up to meet our customer-driven specifications.

Inogen is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. We estimate that more than 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy. Our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. We believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. With each step we take to improve our products and service, our customers take another step toward more freedom.

Hicuity Health - The New Name of Advanced ICU Care - is the nation’s leading provider of high acuity telehealth services, serving approximately 100 hospitals in 26 states on a 24 x 7 x 365 basis. Hicuity Health is a technology-enabled clinical services provider that employs cutting edge tele-technology, experienced US board-certified intensivists, multiple dedicated tele-care delivery centers, and a proven implementation and client service approach to the benefit of patients, families, providers and hospitals.

Convergent Dental, Inc. is a privately owned dental equipment and technology company. The Company’s flagship product, Solea®, is the only CO2 laser to be cleared by the FDA for all-tissue indications and delivers virtually anesthesia-free, blood-free, pain-free experiences that dentists can rely on. Convergent Dental unites this novel technology with our unique Success Support community, enabling dentists to elevate and grow their practices through improved efficiency, patient experience, clinical effectiveness, and procedural expansion. CONTACT US Convergent Dental 100 Fifth Ave, Suite 1010 Waltham, MA 02451 P: 800.880.8589 E: info@convergentdental.com For the most up-to-date Career Postings, please visit our website.

NavvTrack® is an indoor navigation and location services technology for hospitals and health systems that uses Indoor Positioning technology (IPS) to provide Care Traffic Control. The platform, called NavvTrack®, was conceived at 877-bed Henry Ford Hospital and is being used to optimize patient transport, housekeeping, and central pharmacy deliveries. Henry Ford Hospital is 17-floors covering a total of 3,000,000 square feet and a part of the 6-hospital Henry Ford Health System. At Henry Ford Health System, NSI is partnering with Apple to leverage the “indoor GPS” to optimize mobile workflows and enable real-time healthcare. The platform requires no new infrastructure and can be enabled in a short time.

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.

SI-BONE® is focused on helping patients in one of the most under-served, under-diagnosed, and under-treated areas in orthopedics, the sacroiliac (SI) joint. SI-BONE developed an innovative, patented implant to fuse the SI joint. The iFuse Implant System® provides a less invasive alternative to traditional sacroiliac (SI) joint fusion surgery and has been used in over 65,000 procedures to date. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit. For additional information on the company or the products including risks and benefits, please visit www.si-bone.com/risks. We are aware of active recruitment scams using the SI-BONE name, in which individuals pose as our recruiters and post fake remote job openings and make fake job offers on the Internet. Please note, we will never make an offer of employment without conducting multiple rounds of interviews face-to-face using secure video-conferencing technology. We will never ask candidates to cash checks or make a payment in order to be considered for a position. SI-BONE only uses company email addresses, which contain “@si-bone.com” to communicate with candidates. If you believe you’ve been a victim of a phishing scam, please visit the Cybersecurity & Infrastructure Security Agency at https://www.cisa.gov/be-cyber-smart/report-incident learn how to report it.

At iQue® (formerly Intellicyt), our mission is to enable bioscience enterprises to rapidly and cost effectively screen and profile disease- and physiologically-relevant model systems for phenotypic endpoints using cell-based and/or bead-based assays. We do this by providing easy-to-use hardware, software, and reagent systems that are optimized to conserve precious samples, use less reagent, and to minimize time-to-answer to both enhance workflow productivity and to preserve the biology of interest. All major pharmaceutical companies and many biotechnology companies and academic institutions have invested in iQue® Advanced Flow Cytometry Platform solutions, to give their cell-based screening campaigns the edge.